Nirsevimab for preventing respiratory syncytial virus lower respiratory tract infections in infants: a systematic review and meta-analysis

BackgroundRespiratory syncytial virus (RSV) causes lower respiratory tract infections (LRTIs) in infants, leading to substantial morbidity and mortality. Nirsevimab, a long-lasting monoclonal antibody, has been demonstrated to reduce RSV-related outcomes in randomized controlled trials (RCTs) and re...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Samira Soudani, Lorenzo Bertizzolo, Mehdi Ghemmouri, Mary Chappell, Rachael McCool, Katie Reddish, Paul Miller, Erin Barker, Harriet Fewster
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Frontiers Media S.A. 2025-10-01
Serie:	Frontiers in Public Health
Soggetti:	nirsevimab observational studies systematic review meta-analysis RSV
Accesso online:	https://www.frontiersin.org/articles/10.3389/fpubh.2025.1641085/full
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!